In this GEN Market & Tech Analysis report we examine the trajectory of next-generation sequencing (NGS) as it migrates from the research environment toward the clinic.
Highlights of this report:
- The NGS field received a major boost with the first U.S. FDA approval granted to Illumina’s MiSeqDx system.
- This development will further drive forward the deployment of NGS for clinical testing and result in more publications in this field with clinical samples.
- Even though cancer is the major driver of the NGS space currently in the clinical segment, this will expand to include other disease areas, most notably in the case of genetic diseases as well as infectious agent characterization.
- The migration toward the clinic means that more clinical tests using NGS for mutation analysis are predicted downstream.
CLICK HERE to download the PDF report.
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at firstname.lastname@example.org.